Mr Mrs Miss Ms Dr Other

Dr
Oliver
Chammas

Patent Attorney

London Office

Life sciences

Telephone. +44(0) 207 776 5100
Email. ochammas@hgf.com
UPC Representative
Our team of specialist European patent litigators, oppositions specialists and patent attorneys bring together an extensive depth of legal and technical knowledge and are qualified to represent you in the UPC.
Vcard
Linkedin

Experience

Oliver is a chartered UK and European Patent Attorney who joined the London Office in September 2020. Oliver has a PhD in Bio-Nanotechnology and a degree in Medical Biochemistry from the University of Leeds. He has a wide range of experience in prosecution, contentious matters, drafting and freedom-to-operate.

Oliver has worked in private practice in IP for four years in both London and Yorkshire with a number of clients ranging from start-ups and universities to multinational companies.

Oliver's main area of focus is nanoscale biotechnology but he has also had experience with technologies such as biologics, medical devices, medical treatments, diagnostic and analytical methods, antibody technology and second medical use inventions for a range of diseases.

Oliver has experience of patent prosecution in the UK and Europe as well as advising clients as to patent prosecution in foreign jurisdictions including the United States, Japan and China.

Specialisms

Industries

Services

Qualifications

Patent Attorney

Chartered (UK)
Europe

BSC

Medical Biochemistry - University of Leeds

MSC

Integrated PhD & MSc – Molecular Scale Engineering – University of Leeds

PHD

Thesis entitled “Atomic Force Microscopy of DNA-protein Interactions” – University of Leeds

POSTGRADUATE DIPLOMA OR CERTIFICATE

Post-Graduate Certificate in Intellectual Property - Queen Mary University of London

Publications

IP Ingredients: The not so "Impossible" Burger

View publication online

Related News

PRESS RELEASE – HGF strengthens European presence with three new Partners in France and Germany

HGF is pleased to announce the arrival of three new partners, further strengthening its European presence. Two partners will be joining the firm’s fast-growing French practice, and one will join …

Read article

G1/23: The Enlarged Board of Appeal shift EPO practice towards an “on-sale” bar.

Last week, the EPO’s Enlarged Board of Appeal (EBA) issued its Decision that both a product put on the market before the date of filing of a European patent application, …

Read article

The EPO Board of Appeal comments on the scope of the morality exclusion from patentability

The recent decision, T1553/22 of the Board of Appeal required the Board to consider the scope of the exclusions from patentability under Article 53(a) EPC. The invention in this case …

Read article
Event - 11th November 2025

OIS Investor Forum - Jeffries

HGF is proud to be sponsoring the OIS Investor Forum on 18th November. One of the premier gatherings for leaders, innovators, and investors across the healthcare industry. The forum covers …

Event details

From Stripes to Supermarkets: The Court of Appeal Reaffirms the Need for Precision in Trade Mark Law

On 23 October 2025, Lord Justice Arnold delivered two landmark Court of Appeal decisions addressing trade mark registrability: Thom Browne Inc & Anor v adidas AG [2025] EWCA Civ 1340 …

Read article

Protecting Digital Health innovation in the AI revolution

As artificial intelligence (AI) continues to transform healthcare, from diagnostic imaging and drug discovery to wearable devices and clinical decision support, questions around how to protect these advancements have become …

Read article

Doubling Up on Added Matter at the UPC

Following the UPC Court of Appeal (CoA) decision in Abbott v Sibio (APL_39664/2024, 14 February 2025) we now have a second CoA decision on added matter in expert Klein v …

Read article
See all updates

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.

Contact us